Q
QuantAbundance

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

31,229 signal articles · 0 in last 24h · 160,153 total before filter · latest 3d ago
0last 24h
474last 7d
62● bullish (7d)
54● bearish (7d)
214publishers
AllMacro87Earnings138M&A48Regulatory6Product7Analyst15
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
E-Commerce Update - AI-Powered Student Spaces Revolutionizes Learning With Adobe Acrobat
Simply Wall St.18d agoneutral
E-Commerce Update - AI-Powered Student Spaces Revolutionizes Learning With Adobe Acrobat

Adobe has globally launched Student Spaces in Acrobat for free, providing students a trusted, AI-driven study platform that leverages decades of Adobe's document expertise. Initially released in beta in April 2026, the platform rapidly gained traction with more than 1 million monthly users, offering tools like adaptive flashcards, citation generation, and study guide creation to optimize learning. The latest features aim to enhance learning efficiency, ensure information authenticity, and...

CoreWeave Signs New Compute Contracts at Approximately $40 Million per Megawatt
InvestorsHub18d agoneutral
CoreWeave Signs New Compute Contracts at Approximately $40 Million per Megawatt

CoreWeave (NASDAQ:CRWV) has reported signing new computing capacity contracts at higher prices since 30 June 2026, as the company expands its commitments to customers requiring artificial intelligence infrastructure. During the third quarter of 2026, CoreWeave entered into short-term customer agreements lasting approximately three to six months, with pricing equivalent to around $40 million per megawatt.

Novo Nordisk Publishes Phase 3b Denecimig Results in Haemophilia A
InvestorsHub18d agoneutral
Novo Nordisk Publishes Phase 3b Denecimig Results in Haemophilia A

Novo Nordisk (NYSE:NVO) has published results from its phase 3b FRONTIER5 study of investigational treatment denecimig in the Journal of Thrombosis and Haemostasis, reporting safety, laboratory and patient-experience findings in people with haemophilia A. The study examined whether patients could switch directly from emicizumab to denecimig without requiring a washout period or an initial loading dose.

Why banks blew it on the Clarity Act, while crypto brokers operate as normal
Yahoo Finance Video18d agoneutralVIDEO
Why banks blew it on the Clarity Act, while crypto brokers operate as normal

Scott Melker and Coinbase (COIN) CEO Brian Armstrong discuss how big banks fumbled the Clarity Act by getting caught up in stablecoin rewards, potentially leaving themselves worse off as crypto brokers continue operating as usual. "The Daily Wolf with Scott Melker" airs every day at 12:00 p.m. Tune in for your daily dose of all things crypto.

3 Out-of-Favor Stocks with Warning Signs
StockStory18d agoneutral
3 Out-of-Favor Stocks with Warning Signs

Rock-bottom prices don’t always mean rock-bottom businesses. The stocks we’re examining today have all touched their 52-week lows, creating a classic investor’s dilemma: bargain opportunity or value trap?

Investing.com18d agoneutral
CoreWeave’s tug-of-war: Record pricing power battles a $3B debt cloud

Investing.com -- CoreWeave (CRWV) shares edged up just 1% on Thursday, caught in a direct clash between red-hot AI compute demand and the heavy gravitational pull of looming dilution. CoreWeave proved exactly how starved the AI market is for capacity. The company revealed it secured short-term Q3 contracts at a staggering $40 million per megawatt in annualized revenue. On top of that premium pricing, CoreWeave racked up over $25 billion in net new customer commitments early in Q3 and expanded it

What's Happening With NBIS Stock?
Trefis18d agoneutral
What's Happening With NBIS Stock?

Nebius Group (NBIS) jumped over 6% in extended trading on September 16 following revised pricing strategies across its on-demand AI compute resources. Yet, the stock remains down roughly 22% over the trailing month due to balance sheet stress, equity dilution fears, and sector rotation. The central tension remains execution: can Nebius convert its massive backlog into revenue before heavy capital commitments squeeze liquidity.

A $289 Billion Reason to Buy RTX Stock
Barchart18d agobullish
A $289 Billion Reason to Buy RTX Stock

Speaking at Morgan Stanley’s Laguna Conference, RTX CEO Chris Calio highlighted a $289 billion backlog that could support the company’s growth for years.